R1507 antibody

Manufactured by Roche

The R1507 antibody is a laboratory reagent used in scientific research. It is a monoclonal antibody that binds to a specific target protein or antigen. The core function of the R1507 antibody is to serve as a tool for the detection, identification, or quantification of the target molecule in various experimental settings. This description is factual and unbiased, without any interpretation or extrapolation on the intended use of the product.

Automatically generated - may contain errors

Lab products found in correlation

Bms 754807, by Bristol-Myers Squibb (1 mentions) Dasatinib, by LC Laboratories (1 mentions) Azd0530, by LC Laboratories (1 mentions)

2 protocols using r1507 antibody

R1507 Antibody Procurement Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

R1507 antibody was obtained from Hoffman-La Roche Inc. (Nutley, NJ).

Heske C.M., Yeung C., Mendoza A., Baumgart J.T., Edessa L.D., Wan X, & Helman L.J. (2016). The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma. Translational Oncology, 9(6), 540-547.

+ Open protocol

+ Expand

Small Molecule Inhibitor Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols

AZD0530, dasatinib, and Gleevec were purchased from LC Laboratories (Woburn, MA). R1507 antibody was obtained from Roche Inc (Nultey, NJ), and h7C10 antibody was obtained from Merck Inc (Kenilworth, NJ). BMS-754807 was obtained from Bristol-Myers Squibb Inc (New York, NY).

Wan X., Yeung C., Heske C., Mendoza A, & Helman L.J. (2015). IGF-1R Inhibition Activates a YES/SFK Bypass Resistance Pathway: Rational Basis for Co-Targeting IGF-1R and Yes/SFK Kinase in Rhabdomyosarcoma. Neoplasia (New York, N.Y.), 17(4), 358-366.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!